Alzheimer Disease
Conditions
Brief summary
Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.
Detailed description
This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73. In addition, safety assessments, pharmacokinetic (PK) assessments and collections of CSF and blood markers of AD pathophysiology before and after treatment will be performed.
Interventions
Oral capsule
Oral capsule
DRUGPlacebo oral capsule
Oral capsule
Sponsors
Anavex Australia Pty Ltd.
Anavex Germany GmbH
Anavex Canada Ltd.
Anavex Life Sciences Corp.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
There will be blinding procedures for this study. Capsules will be indistinguishable from active ingridient containing capsules.
Intervention model description
Randomized 1:1:1 to two different ANAVEX2-73 doses or placebo
Eligibility
Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 60 to 85 years, inclusive, with a NIA-AA diagnosis of mild cognitive impairment (MCI) due to AD or early stage mild dementia due to AD. AD diagnosis should be made by an appropriately qualified medical specialist and AD pathology should be confirmed by either: 1. Historical records of amyloid CSF assessment or 2. Historical records of amyloid PET scan or 3. If neither historical records are available, then AD pathological diagnosis confirmation should be offered at screening: i. CSF collection or ii. Amyloid PET iii. Past medical records of MRI or CT are optional. * Mini Mental State Examination (MMSE) score between 20-28, inclusive. * Free Recall score ≤17 or Total Recall score \<40 on the Free and Cued Selective Reminding Test (FCSRT). * Participants are either outpatients, or residents of an assisted-living facility. Participant has a designated study partner, who spends at least 10hrs per week with the participant, in order that assessments e.g. carer burden instruments are completed with true knowledge of the participant. * No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without specific plan, or active suicidal thought(s) with plan and intent) OR suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior). * Confirmation from the participant that, if of childbearing potential is not pregnant through urine pregnancy testing.
Exclusion criteria
* Patients who have a progressive medical or neurological condition that in the opinion of the investigator would interfere with the conduct of the study. Exception: If diagnosed with seizures, must be on stable anti-seizure medication for at least 3 months prior to screening. * Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study. * History or clinically evident stroke or clinically significant carotid or vertebrobasilar stenosis or plaque. * History of neurologic (e.g. stroke, traumatic brain injury) or psychiatric condition that the investigator deems may interfere with interpretability of data. * History of untreated thyroid disorder, Type 1 diabetes, and insulin dependent or uncontrolled Type II diabetes, as determined by the investigator (e.g. non-insulin-controlled Type II diabetes, whose HbA1c value is higher than 8.0%). * Body Mass Index (BMI) \> 30. * History of clinical hepatic dysfunction. * Current symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hematological or hormonal disorders. * Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3x upper limit of normal (ULN) as determined during screening. * Significant history of drug addiction (with the exception of nicotine dependence) or abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator) within the last two years prior to informed consent, or a positive urine drug screen for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening. Prescription medication yielding a positive drug screen are acceptable except for tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin) Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)). * Clinically significant infection within the last 30 days prior screening (e.g., chronic persistent or acute infection, urinary tract infections (UTI)). * Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years. * Myocardial infarction within the last year. * History of cancer within the last 3 years, with the exception of basal cell carcinoma and non-metastatic squamous cell carcinoma of the skin and prostate cancer with currently normal PSA. * Other clinically significant abnormality on physical, neurological, laboratory, or electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise the study or be detrimental to the participant. * Hemoglobin \< 11 g/dL. * Have any contraindication to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in skull and cardiac devices or severe claustrophobia). * Smoking \> 1 pack of cigarettes per day (as assessed for the 30 days prior to screening). * Alcohol use of more than 2 drinks per day. * Current use of over-the-counter (OTC) supplements or nutraceuticals unless they are on stable dose for at least 3 months prior to screening and are documented in the eCRF. * Use of over the counter (OTC) or prescription medication for sleep on 2 or more occasions per week. * Being treated with psychoactive medications on a stable dose for less than 3 month. * Any prior exposure to ANAVEX2-73. * Individuals enrolled in previous AD clinical trial involving an investigational drug treatment less than 3 months ago (longer than 3 month ago allowed). * Any known hypersensitivity to any of the excipients contained in the study drug formulation. * Any other criteria (such as a clinically significant screening blood test result), which in the opinion of the Investigator causes the participant not to qualify for the study. * Evidence of cerebrovascular dementia with a Hachinski score of 4 or more.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition) | 48 weeks | Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) |
| ADCS-ADL (Activities of Daily Living) | 48 weeks | Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) | 48 weeks | Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | 48 weeks | Assess the safety and tolerability of ANAVEX2-73 compared to placebo |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with change of brain volume assessed by MRI | 48 weeks | To evaluate the effect of ANAVEX2-73 on structural and Arterial Spin Labeling (ASL) MRI scan assessments characteristic for AD pathophysiology compared to placebo over a 48-week treatment duration |
| RSCAQ sleep score | Weeks 0, 4, 12, 24, 36, and 48 | To evaluate whether ANAVEX2-73 improves sleep continuity as assessed on a serial basis (weeks 0, 4, 12, 24, 36, and 48) with a questionnaire that assess reported sleep continuity (RSCAQ) |
| Blood assessment | 48 weeks | Blood assessment from baseline and compared to placebo at +48 weeks: Abeta40, Abeta42, T-tau, NFL, YKL-40, BACE1 concentration |
| CSF assessment | 48 weeks | Changes in CSF parameters (Abeta40, Abeta42, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1 concentration) characteristic for AD pathophysiology from baseline and compared to placebo at +48 weekstreatment differences within subgroups will be performed |
| Number of participants with pre-specified genetic variants | 48 weeks | AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed |
Countries
Australia, Canada, Germany, Netherlands, United Kingdom
Outcome results
None listed